Aging in men is accompanied by a progressive, but individually variable decline of serum
testosterone production, more than 20% of healthy men over 60 yr of age presenting with …

Prostate cancers that are progressing on medical and surgical therapies designed to ablate
the action of androgens continue to express androgen receptor (AR) and to depend on …

For several decades, androgen deprivation (AD) has been the mainstay for treating
metastatic prostate cancer. AD can be attained by a variety of means; however, irrespective …

Over the past 20 years, research on hormonal treatments for prostate cancer focused on
maximizing androgen ablation through combination therapy. Unfortunately, maximal …

OBJECTIVE To assess the feasibility and tolerability of intermittent androgen suppression
therapy (IAS) in prostate cancer. PATIENTS AND METHODS Patients with recurrent or …

Written by over 250 of the world's leading urologists and uro-oncologists from the USA,
Canada, UK, Austria, Belgium, Finland, France, Germany, Ireland, Italy, the Netherlands and …

At present, the management of non-organ confined prostate cancer, whether it is a
recurrence or metastasis, continues to evolve based on prostate cancer detection using …

PURPOSE To clarify the optimal duration and methods for adjuvant endocrine therapy after
external beam radiation therapy (EBRT) in patients with locally advanced prostate cancer …

OBJECTIVES: To analyze the oncologic results of intermittent androgen deprivation (IAD) for
biochemical recurrence after radical prostatectomy (RP). METHODS: A total of 57 patients …

Introduction: To assess the effects of intermittent maximal androgen blockade (IMAB) on
testosterone (T) levels during on-and off-treatment periods. Materials and Methods: A total of …